Skip to main content

Table 6 Annual transitions (stated as percentages)

From: Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US

Transition Baseline Range Reference
Chronic Hepatitis C    
 to Compensated Cirrhosis 7.30 % 1.0 %-23.2 % [6, 25]
Compensated Cirrhosis    
 to Decompensated Cirrhosis 3.90 % 2.0 %-8.3 % [22, 25, 29]
 to HCC 3.70 % 1.0 %-4.4 % [25, 30, 31]
Decompensated Cirrhosis    
 to HCC 3.70 % 1.0 %-4.4 % [25, 29, 30]
 to Liver Transplant 3 % 1.0 %-6.2 % [22, 25]
 to Liver-induced Death 12.90 % 6.5 %-19.3 % [15, 22, 24, 29]
HCC    
 to Liver Transplant 3 % 1.0-6.2 % [22, 25]
 to Liver-induced Death 42.70 % 33 %-86 % [25, 29]
Liver Transplant    
 to Liver-induced Death, first year 13.70 % 6 %-42 % [25, 32]
 to Liver-induced Death, successive year 5.20 % 2.4 %-11 % [25, 32]